We read with interest the report by Stone et al 1 that showed a highly significant association between the development of Q-wave myocardial infarction (QWMI) and creatine kinase (CK)-MB values Ͼ8 times the upper limit of normal after percutaneous intervention (PCI) with in-hospital and late (up to 2 years) mortality.
To the Editor:
We read with interest the report by Stone et al 1 that showed a highly significant association between the development of Q-wave myocardial infarction (QWMI) and creatine kinase (CK)-MB values Ͼ8 times the upper limit of normal after percutaneous intervention (PCI) with in-hospital and late (up to 2 years) mortality.
Evidence of an increased risk of adverse clinical outcome with asymptomatic rises of CK and CK-MB after PCI has previously been clearly documented. 2, 3 We studied the release of the highly sensitive and specific cardiac troponin I (cTnI) in a series of 344 consecutive patients presenting with stable angina and undergoing elective PCI (balloon angioplasty, stent insertion, and rotational atherectomy). 4 We measured cTnI before PCI and at 6, 14, and 24 hours after PCI. cTnI was elevated in 61 (17.7%) patients after PCI in our series, which was comparable to a postprocedural CK-MB rise in 17.9% of patients in the study by Stone et al. 1 We found a post-PCI cTnI elevation of Ͼ0.2 g/L (manufacturers' recommended clinically discriminant value) to be strongly predictive of adverse events (death, QWMI, and repeat revascularization) at a mean follow-up period of 44.5 (Ϯ17.7) weeks. The positive predictive value (PPV) of post-PCI cTnI elevation for adverse events was 0.47, and the negative predictive value (NPV) was 0.96 (PϽ0.0001; OR 18.9, 95% CI 9.7 to 37).
This association seemed to be independent of angiographic procedural complications. Angiographic events occurred in 79 (23%) of our patients. In 40 (15%) of the remaining 265 patients, cTnI was elevated to Ͼ0.2 g/L within 24 hours after PCI in the absence of angiographic complications. The occurrence of angiographic complications had a PPV for adverse events of 0.30 and a NPV of 0.93 (Pϭ0.0003; OR 4.4, 95% CI 2.2 to 8.6). The combination of both angiographic complications and postprocedural cTnI elevation gave a PPV for adverse events of 0.69 and a NPV of 0.92 (Pϭ0.005; OR 22.6, 95% CI 2.6 to 68.5). We did not demonstrate a significant relationship between the type of procedural device and postprocedural cTnI elevation.
Our data add to a growing body of evidence showing that asymptomatic postprocedural myocardial cell injury does have important prognostic implications and would support the need for routine troponin measurements after PCI. 
